SC
SCL Science Inc.
246960 | KO
Overview
Corporate Details
- ISIN(s):
- KR7246960009
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 영등포구 선유로13길 25 에이스하이테크시티 2차 1209호, 서울특별시
- Website:
- https://sclscience.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-11 00:00 |
M&A Activity
타법인주식및출자증권취득결정(자율공시)
|
Korean | 16.2 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-14 00:00 |
Regulatory Filings
단일판매ㆍ공급계약체결
|
Korean | 10.4 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 13.7 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.3 KB | ||
| 2025-08-11 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 114.2 KB | ||
| 2025-07-28 00:00 |
Delisting Announcement
주권매매거래정지 (영업양수도)
|
Korean | 4.8 KB | ||
| 2025-07-28 00:00 |
M&A Activity
주요사항보고서(영업양수결정)
|
Korean | 18.8 KB | ||
| 2025-07-21 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(무상증자결정)
|
Korean | 15.0 KB |
Automate Your Workflow. Get a real-time feed of all SCL Science Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SCL Science Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SCL Science Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.
United States of America
RADX
United States of America
RADX
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
United States of America
RFL
Develops ionization tech to generate rain and mitigate fog for water-scarce regions.
United States of America
RAIN
United States of America
RAIN
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
United States of America
RLYB
United States of America
RLYB
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Japan
4579
AI-driven biotech accelerating drug discovery for rare diseases and oncology.
United States of America
RXRX
United States of America
RXRX
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
United States of America
RLMD
Develops a device platform for delivering targeted therapies directly to solid tumors.
United States of America
RNXT
United States of America
RNXT
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
United States of America
RPTX
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
United States of America
REPL